Evidence map›Paper›PMID 36712053›Full record

ArticlebioRxiv : the preprint server for biology2023

Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.

Jackson Nyman, Thomas Denize, Ziad Bakouny, Chris Labaki, Breanna M Titchen, Kevin Bi, Surya Narayanan Hari, Jacob Rosenthal, Nicita Mehta, Bowen Jiang and 8 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jackson NymanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Thomas DenizeDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Ziad BakounyDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Chris LabakiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breanna M TitchenHarvard Graduate Program in Biological and Biomedical Sciences, Boston, MA, USA.
Kevin BiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Surya Narayanan HariDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacob RosenthalDepartment of Informatics & Analytics, Dana-Farber Cancer Institute, Boston, MA, USA.
Nicita MehtaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Bowen JiangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Bijaya SharmaImmunoProfile, Department of Pathology, Brigham & Women's Hospital and Dana-Farber Cancer Institute, Boston, MA.
Kristen FeltImmunoProfile, Department of Pathology, Brigham & Women's Hospital and Dana-Farber Cancer Institute, Boston, MA.
Renato UmetonDepartment of Informatics & Analytics, Dana-Farber Cancer Institute, Boston, MA, USA.
David A BraunCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Scott RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sabina SignorettiDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Funding

Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0M
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Molecular Origins and Evolution to Chemoresistance in Germ Cell TumorsR37CA222574 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2024
$3.2M
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0M
Unraveling the influence of genetic subtype on spatial configurations of tissue and immune compartment composition in clear cell renal cell carcinomaF31CA250136 · NCI · HARVARD UNIVERSITY · PI NYMAN, JACKSON · 2020 to 2022
$97k
NCI NIH HHS F31 CA250136NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA227388NCI NIH HHS R37 CA222574NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is molecularly heterogeneous, immune infiltrated, and selectively sensitive to immune checkpoint inhibition (ICI). Established histopathology paradigms like nuclear grade have baseline prognostic relevance for ccRCC, although whether existing or novel histologic features encode additional heterogeneous biological and clinical states in ccRCC is uncertain. Here, we developed spatially aware deep learning models of tumor- and immune-related features to learn representations of ccRCC tumors using diagnostic whole-slide images (WSI) in untreated and treated contexts (n = 1102 patients). We discovered patterns of nuclear grade heterogeneity in WSI not achievable through human pathologist analysis, and these graph-based "microheterogeneity" structures associated with PBRM1 loss of function, adverse clinical factors, and selective patient response to ICI. Joint computer vision analysis of tumor phenotypes with inferred tumor infiltrating lymphocyte density identified a further subpopulation of highly infiltrated, microheterogeneous tumors responsive to ICI. In paired multiplex immunofluorescence images of ccRCC, microheterogeneity associated with greater PD1 activation in CD8+ lymphocytes and increased tumor-immune interactions. Thus, our work reveals novel spatially interacting tumor-immune structures underlying ccRCC biology that can also inform selective response to ICI.

Identifiers

PMID36712053
PMCPMC9882334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.